IMUX - Immunic, Inc.
| Previous Close | 14.10 |
| Open | 14.12 |
| Bid | 0.00 x 1200 |
| Ask | 0.00 x 1400 |
| Day's Range | 13.94 - 14.46 |
| 52 Week Range | 6.04 - 360.00 |
| Volume | 16,986 |
| Avg. Volume | 153,918 |
| Market Cap | 145.952M |
| Beta (3Y Monthly) | 2.73 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -11.31 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 45.00 |
- PR Newswire
Immunic, Inc. Announces First Patient Enrolled in Investigator-Sponsored Proof-of-Concept Clinical Trial of IMU-838 for the Treatment of Patients with Primary Sclerosing Cholangitis
IMU-838 is an orally available, next-generation selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme dihydroorotate dehydrogenase (DHODH). PSC is a progressive disease of the liver with unknown cause and a prevalence of about 4.15 per 100,000 in the United States.
- PR Newswire
Immunic, Inc. Reports Second Quarter 2019 Financial Results and Highlights Recent Activity
SAN DIEGO , Aug. 8, 2019 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing potentially best-in-class oral therapies for the treatment of chronic ...
- PR Newswire
Immunic AG Awarded Research Grant by German Federal Ministry of Education and Research in Support of the InnoMuNiCH Project
SAN DIEGO, Aug. 1, 2019 /PRNewswire/ -- Immunic, Inc. (IMUX), a clinical-stage biopharmaceutical company focused on developing potentially best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced that the German Federal Ministry of Education and Research has awarded its subsidiary, Immunic AG, a grant in the amount of up to EUR 653,535 (approximately USD 730,000) in support of the InnoMuNiCH (Innovations through Munich-Nippon Cooperation in Healthcare) project. The InnoMuNiCH project is coordinated by BioM Biotech Cluster Development GmbH and supported by the Ministry of Education and Research, as part of the funding program, "Internationalization of Leading-Edge Clusters, Forward-Looking Projects and Other, Comparable Networks." The goal of the project is to accelerate global biopharmaceutical innovations by pooling German-Japanese competencies in research and development.
- PR Newswire
Immunic, Inc. to Present at the Canaccord Genuity 39th Annual Growth Conference on August 8
SAN DIEGO, July 30, 2019 /PRNewswire/ -- Immunic, Inc. (IMUX), a clinical-stage biopharmaceutical company focused on developing potentially best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced that Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic, will present at the Canaccord Genuity 39th Annual Growth Conference in Boston on Thursday, August 8, 2019 at 2:30 pm EDT. Immunic, Inc. (IMUX) is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis.
- Simply Wall St.
Could Immunic, Inc.'s (NASDAQ:IMUX) Investor Composition Influence The Stock Price?
If you want to know who really controls Immunic, Inc. (NASDAQ:IMUX), then you'll have to look at the makeup of its...
- PR Newswire
Immunic, Inc. Appoints Sanjay S. Patel, CFA, as Chief Financial Officer
SAN DIEGO, July 16, 2019 /PRNewswire/ -- Immunic, Inc. (IMUX), a clinical-stage biopharmaceutical company focused on developing potentially best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced the appointment of Sanjay S. Patel, CFA, as Chief Financial Officer, effective July 15, 2019. Mr. Patel replaces Tamara A. Seymour, who has served as the company's Interim Chief Financial Officer since April 26, 2019. With a deep well of C-Suite and investment banking experience, Sanjay's proven track record, strong knowledge base and established industry relationships will be especially important as we continue to move our pipeline, including our lead compound, IMU-838, through the clinic and prepare for a number of value-creating milestones in the coming year and beyond," stated Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic.
- PR Newswire
Immunic, Inc. to Present Previously Unpublished Data Regarding Lead Program, IMU-838, at the GI Inflammatory Diseases Summit in Boston
SAN DIEGO, June 24, 2019 /PRNewswire/ -- Immunic, Inc. (IMUX), a clinical-stage biopharmaceutical company focused on developing potentially best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, announced that Hella Kohlhof, Ph.D., Chief Scientific Officer of Immunic, will present today previously unpublished data regarding the company's lead program, IMU-838, at the GI Inflammatory Diseases Summit (GIIDS) in Boston. The presentation, entitled, "IMU-838 in Clinical Phase 2 – New Selective Oral Treatment for IBD," will take place at 3:30 pm ET. IMU-838, currently in phase 2 clinical development for the treatment of ulcerative colitis (UC) and relapsing-remitting multiple sclerosis (RRMS), is an orally available, next-generation selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme dihydroorotate dehydrogenase (DHODH).
- PR Newswire
Immunic, Inc. Files Financial Statements and Pro Forma Financial Information in Accordance with Previously Completed Stock-for-Stock Exchange Transaction and Provides Corporate Update
SAN DIEGO, June 21, 2019 /PRNewswire/ -- Immunic, Inc. (IMUX), a clinical-stage biopharmaceutical company focused on developing potentially best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced that it has filed an amended Current Report on Form 8-K containing certain financial statements and pro forma financial information required to be provided in connection with the stock-for-stock exchange transaction between Immunic, Inc. (then known as Vital Therapies, Inc.) and Immunic AG, which was completed on April 12, 2019. Management also provided an update on the progress of its key development programs.
- PR Newswire
Immunic, Inc. to Present Newly Available Preclinical Data for IMU-935 in Poster Presentation at the 2ⁿᵈ Conference on Molecular Mechanisms of Inflammation in Trondheim, Norway
- Results confirm IMU-935 as a potent inverse agonist of ROR ϒt with an IC 50 of 24 nM, leading to potent inhibition of Th17 differentiation while allowing normal thymocyte maturation - - In addition to ...
- PR Newswire
Immunic, Inc. to Participate in Investor and Scientific Conferences in June
June 3-6: 2nd Conference on Molecular Mechanisms of Inflammation: Hella Kohlhof, Ph.D., Chief Scientific Officer of Immunic, will present newly available preclinical data on IMU-935, an orally available, inverse agonist of RORγt for the treatment of various inflammatory and autoimmune diseases. The poster presentation will take place at the 2nd Conference on Molecular Mechanisms of Inflammation in Trondheim, Norway on Tuesday, June 4, beginning at 6:00 pm CEST.
- PR Newswire
Immunic, Inc. to Participate in Upcoming May Conferences
May 18-21: Digestive Disease Week® (DDW): Dr. Andreas Muehler, Chief Medical Officer of Immunic, will attend the DDW conference, being held at the San Diego Convention Center in San Diego. May 20-21: BioEquity Europe 2019: Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic, will present a company overview at 5:15 pm CEST on May 20 at the 20th Annual BioEquity Europe conference, being held at the Crowne Plaza Barcelona Fira Center Hotel in Barcelona, Spain.
- PR Newswire
Immunic, Inc. Appoints Industry Veteran Tamara A. Seymour as Interim Chief Financial Officer
SAN DIEGO, April 29, 2019 /PRNewswire/ -- Immunic, Inc. (IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced the appointment of Tamara A. Seymour, MBA, as its Interim Chief Financial Officer, effective April 26, 2019. "Ms. Seymour has a proven track record of guiding public and privately-held life sciences companies through their corporate life cycles, including capital raising, negotiating complex strategic transactions, setting and maintaining internal fiscal policy and driving revenue growth," stated Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic.
